- Home
- RVNC vs HPS Comparison
RVNC vs HPS Comparison
Compare RVNC & HPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVNC
- HPS
- Stock Information
- Founded
- RVNC 1999
- HPS 2003
- Country
- RVNC United States
- HPS United States
- Employees
- RVNC N/A
- HPS N/A
- Industry
- RVNC Biotechnology: Pharmaceutical Preparations
- HPS Investment Managers
- Sector
- RVNC Health Care
- HPS Finance
- Exchange
- RVNC Nasdaq
- HPS Nasdaq
- Market Cap
- RVNC 320.5M
- HPS 521.2M
- IPO Year
- RVNC 2014
- HPS N/A
- Fundamental
- Price
- RVNC $3.09
- HPS $14.95
- Analyst Decision
- RVNC Hold
- HPS
- Analyst Count
- RVNC 9
- HPS 0
- Target Price
- RVNC $8.45
- HPS N/A
- AVG Volume (30 Days)
- RVNC 3.6M
- HPS 58.4K
- Earning Date
- RVNC 11-07-2024
- HPS 01-01-0001
- Dividend Yield
- RVNC N/A
- HPS 8.62%
- EPS Growth
- RVNC N/A
- HPS N/A
- EPS
- RVNC N/A
- HPS N/A
- Revenue
- RVNC $256,945,000.00
- HPS N/A
- Revenue This Year
- RVNC $11.28
- HPS N/A
- Revenue Next Year
- RVNC $27.21
- HPS N/A
- P/E Ratio
- RVNC N/A
- HPS N/A
- Revenue Growth
- RVNC 25.82
- HPS N/A
- 52 Week Low
- RVNC $2.30
- HPS $11.79
- 52 Week High
- RVNC $9.75
- HPS $15.40
- Technical
- Relative Strength Index (RSI)
- RVNC 33.47
- HPS 31.08
- Support Level
- RVNC $3.06
- HPS $14.76
- Resistance Level
- RVNC $3.09
- HPS $15.64
- Average True Range (ATR)
- RVNC 0.11
- HPS 0.17
- MACD
- RVNC 0.02
- HPS -0.05
- Stochastic Oscillator
- RVNC 6.90
- HPS 18.43
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
About HPS John Hancock Preferred Income Fund III Preferred Income Fund III
John Hancock Preferred Income Fund III is a closed-end, diversified management investment company. Its investment objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. It seeks to achieve the objectives by investing a majority of its assets in preferred stocks and other preferred securities, including convertible preferred securities. The portfolio composition of the company consists of the U.S. preferred securities, foreign preferred securities, common stocks, corporate bonds, and the short-term investments.